Hikma Pharmaceuticals PLC operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hikma Pharmaceuticals PLC with three other
companies in this sector in the United Kingdom:
sales of £755.36 million [US$970.90 million]
of which 100%
was Buprenorphine Based Drugs),
(£620.50 million [US$797.56 million]
of which 39%
was Interventional Medicine), and
Croda International Plc
(£1.39 billion [US$1.78 billion]
of which 35%
was Personal Care).
Hikma Pharmaceuticals PLC reported sales of £1.56 billion (US$2.01 billion)
December of 2018.
increase of 4.9%
versus 2017, when the company's sales were £1.49 billion.
Sales at Hikma Pharmaceuticals PLC have increased during each of the previous five years
(and since 2013, sales have increased a total of 79%).
Sales of Generic Pharmaceuticals saw an increase
that was more than double the company's growth rate: sales were up
10.1% in 2018, from
£472.35 million to £520.11 million.
Hikma Pharmaceuticals PLC also saw significant increases in sales in
Others (up 8.7% to £7.52 million)
Not all segments of Hikma Pharmaceuticals PLC experienced an increase in sales in 2018:
sales of Branded Pharmaceuticals fell 1.0% to £407.37 million.